https://doi.org/10.46344/JBINO.2026.v15i02.07

INNOVATIONS IN PREVENTING VASO-OCCLUSIVE CRISES IN SICKLE CELL ANEMIA: BRIDGING MOLECULAR PATHOPHYSIOLOGY AND TREATMENT

***Emmanuel Ifeanyi Obeagu[1,2]**

[1]Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

[2]The Division of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

ABSTRACT

Vaso-occlusive crises (VOCs) represent the hallmark complication of sickle cell anemia (SCA), contributing significantly to morbidity and mortality worldwide. These painful episodes arise from complex molecular and cellular interactions that disrupt microvascular blood flow, causing ischemia and tissue injury. Recent advances in understanding the molecular pathophysiology of VOCs have facilitated the development of innovative therapeutic strategies aimed at prevention and management. This review synthesizes current knowledge of the underlying molecular mechanisms driving vaso-occlusion and highlights emerging pharmacologic and non-pharmacologic interventions designed to mitigate these crises. The intricate pathogenesis of VOC involves abnormal sickling of erythrocytes, endothelial dysfunction, inflammation, adhesion molecule upregulation, and coagulation abnormalities. Targeting these pathways has led to promising therapeutic agents, including anti-adhesive molecules, anti-inflammatory drugs, and novel modulators of hemoglobin polymerization. Gene therapies and genome editing approaches are also on the horizon, offering the potential for durable correction of the underlying genetic defect. Integrative clinical management strategies incorporating pain control, hydration, and disease-modifying therapies remain essential. Future research focusing on precision medicine, biomarker development, and combination therapies holds promise to further improve VOC prevention and patient outcomes. This review underscores the critical importance of bridging molecular insights with clinical applications to transform the care landscape for individuals living with sickle cell anemia.

Keywords: *sickle cell anemia, vaso-occlusive crisis, molecular mechanisms, targeted therapy, clinical management*

Introduction

Sickle cell anemia (SCA) is a hereditary blood disorder characterized by a single nucleotide mutation in the β-globin gene that results in the production of abnormal hemoglobin S (HbS). This mutation causes red blood cells (RBCs) to assume a rigid, sickle-like shape under deoxygenated conditions, impairing their flexibility and leading to obstruction of blood flow within the microvasculature. The hallmark clinical manifestation of SCA is the vaso-occlusive crisis (VOC), an acute episode of severe pain caused by the blockage of small blood vessels. These crises are the predominant cause of morbidity and mortality in individuals with SCA, significantly impacting their quality of life and life expectancy globally [1-3. The pathophysiology of VOCs is complex and multifactorial, involving not only the sickling of RBCs but also a dynamic interplay between erythrocytes, leukocytes, platelets, and the endothelium. Sickled RBCs adhere abnormally to activated endothelial cells expressing adhesion molecules such as selectins and integrins, which further promotes vascular occlusion. In addition, chronic inflammation, oxidative stress, and hypercoagulability contribute to endothelial dysfunction and vascular injury. This multifaceted mechanism underlies the cyclical nature of VOCs, where ischemia and reperfusion injury perpetuate ongoing tissue damage [4-6].

Historically, the management of VOCs has focused primarily on symptomatic treatment with analgesics, hydration, and blood transfusions. While these interventions provide critical relief, they do not address the underlying molecular and cellular events driving vaso-occlusion. Over recent decades, significant advances in molecular biology, genomics, and bioinformatics have enhanced our understanding of VOC pathogenesis, leading to the development of novel targeted therapies. These innovations aim not only to treat acute crises but also to prevent their occurrence by modifying disease pathways at the molecular level [7-8]. Hydroxyurea, the first FDA-approved drug for SCA, marked a turning point in disease management by increasing fetal hemoglobin (HbF) production, thereby reducing the polymerization of HbS and sickling. However, despite its efficacy, hydroxyurea does not completely eliminate VOCs, and some patients do not tolerate or respond adequately to therapy. This has catalyzed the search for additional pharmacologic agents that target adhesion molecules, inflammatory pathways, and oxidative stress, reflecting a more comprehensive approach to disease modification [9-10]. More recently, monoclonal antibodies such as crizanlizumab, which blocks P-selectin-mediated adhesion, and voxelotor, which stabilizes oxygenated hemoglobin, have expanded the therapeutic arsenal against VOCs. Concurrently, gene therapy and gene editing technologies are emerging as potentially curative strategies by either reactivating fetal hemoglobin or correcting the defective β-globin gene itself. These cutting-edge approaches offer hope for durable treatment but also pose challenges related to safety, accessibility, and long-term outcomes [11-12].

Aim

This narrative review aims to comprehensively explore recent innovations in preventing vaso-occlusive crises in sickle cell anemia by bridging molecular pathophysiological insights with emerging therapeutic strategies. Specifically, the review seeks to (1) elucidate the complex molecular and cellular mechanisms underlying vaso-occlusion, (2) highlight novel pharmacologic and gene-based interventions targeting these mechanisms, and (3) discuss current challenges and future directions in translating these advances into effective clinical management. Through this synthesis, the review intends to provide a framework for integrating molecular research with clinical practice to improve outcomes for individuals affected by sickle cell anemia.

Molecular Pathophysiology of Vaso-Occlusion

VOCs in sickle cell anemia (SCA) are initiated by the polymerization of deoxygenated HbS, which causes RBCs to deform into a rigid, sickle shape. This sickling reduces RBC deformability, leading to impaired passage through the microvasculature and increased mechanical obstruction. However, sickling alone does not fully explain the episodic and multifactorial nature of vaso-occlusion. Rather, VOCs arise from complex interactions between sickled erythrocytes, activated endothelial cells, leukocytes, platelets, and the plasma milieu, culminating in a pro-inflammatory and pro-thrombotic microenvironment [13-14]. At the molecular level, the polymerization of HbS triggers oxidative stress within RBCs, resulting in membrane damage and exposure of phosphatidylserine on the cell surface. This altered membrane enhances the adhesion of sickled RBCs to endothelial cells, which express elevated levels of adhesion molecules such as P-selectin, E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1). These adhesion interactions slow blood flow and promote the aggregation of sickled cells, leukocytes, and platelets, further contributing to vascular occlusion. Notably, leukocytes also play an active role, as activated neutrophils and monocytes adhere to endothelium and release pro-inflammatory cytokines and reactive oxygen species (ROS), amplifying endothelial activation and vascular injury [15-16].

Inflammation is a central driver of VOC pathophysiology. Elevated levels of cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) perpetuate endothelial dysfunction and increase the expression of adhesion molecules. Additionally, the coagulation cascade is aberrantly activated in SCA, with increased tissue factor expression and thrombin generation contributing to a hypercoagulable state that predisposes to microthrombosis. The interplay of hemolysis-associated nitric oxide (NO) depletion further exacerbates vasoconstriction and endothelial damage, impairing vasodilation and favoring vaso-occlusion [17-18].

Innovations in Prevention of Vaso-Occlusive Crises in Sickle Cell Disease

Preventing VOCs remains a critical goal in the management of SCD, as these

episodes are major drivers of morbidity, hospitalizations, and long-term organ damage. Recent advances in the molecular understanding of VOCs have catalyzed the development of innovative preventive strategies that target the multifaceted pathophysiology of the disease, moving beyond traditional supportive care [19]. One of the most significant preventive advances has been the optimization and wider implementation of hydroxyurea therapy. Hydroxyurea reduces VOC frequency by increasing HbF levels, which inhibits sickling, and by modulating leukocyte counts and adhesion molecule expression. Recent clinical studies have reinforced its safety and efficacy even in pediatric populations, supporting early initiation to prevent complications before severe disease manifestations occur. Efforts to improve hydroxyurea adherence and accessibility, especially in resource-limited settings, are ongoing to maximize its preventive potential [20].

In addition to hydroxyurea, novel pharmacologic agents designed specifically to prevent VOCs have emerged. Crizanlizumab, a humanized monoclonal antibody against P-selectin, effectively decreases the adhesion of sickled erythrocytes and inflammatory cells to the endothelium, a pivotal event in VOC initiation. Its use has been associated with a significant reduction in VOC frequency in clinical trials, marking a milestone in targeted therapy. Other selectin inhibitors and agents targeting adhesion pathways are in various stages of development, broadening the spectrum of preventive options [21]. Furthermore, advances in gene therapy and gene editing technologies offer the promise of long-term VOC prevention by addressing the genetic root cause of SCD. Techniques such as CRISPR-Cas9-mediated gene correction and lentiviral vectors to induce durable HbF expression are in clinical trials, showing encouraging early results. These approaches, while not yet widely accessible, have the potential to transform VOC prevention by offering curative possibilities [22-23].

Adjunctive strategies that target the inflammatory and oxidative stress components of VOC pathogenesis are also being explored for prevention. Anti-inflammatory drugs, antioxidants, and agents that restore nitric oxide bioavailability aim to maintain endothelial health and reduce the pro-adhesive and pro-thrombotic milieu. Additionally, supportive care interventions such as chronic transfusion therapy remain valuable for high-risk patients to prevent recurrent VOCs and associated complications [24-25]. Comprehensive preventive care now emphasizes multidisciplinary approaches, including patient education, pain management plans, hydration strategies, and psychosocial support, which collectively reduce VOC triggers and improve overall disease management. Incorporating these innovations into clinical practice requires coordinated efforts to address barriers in healthcare delivery and disparities, especially in regions with high SCD prevalence [26].

Innovations in Therapeutic Strategies

Recent advances in understanding the molecular underpinnings of VOCs have

spurred the development of innovative therapeutic strategies that go beyond symptomatic management to target key pathological processes in SCA. These novel interventions aim to prevent the initiation and progression of vaso-occlusion by modulating hemoglobin polymerization, reducing cellular adhesion, attenuating inflammation, and restoring vascular function [27]. Hydroxyurea remains the foundational disease-modifying therapy for SCA, primarily by inducing HbF production, which inhibits HbS polymerization and reduces sickling. Despite its established benefits, limitations such as variable patient response and adherence challenges have driven the search for alternative and adjunctive therapies. Among these, voxelotor, a hemoglobin oxygen-affinity modulator, stabilizes the oxygenated form of HbS, thereby preventing polymer formation and improving RBC deformability. Its approval has introduced a novel mechanism directly targeting the root cause of sickling [28-29].

Another significant advancement is the development of monoclonal antibodies targeting adhesion molecules critical to vaso-occlusion. Crizanlizumab, an anti-P-selectin antibody, reduces the adhesion of sickled erythrocytes and leukocytes to the endothelium, decreasing the frequency of VOCs. This therapeutic exemplifies the strategy of disrupting pathological cell-cell interactions in the microvasculature. Additionally, agents targeting other adhesion pathways, such as selectin inhibitors and integrin blockers, are under active investigation, broadening the armamentarium against vascular occlusion [30-31]. Anti-inflammatory and antioxidant therapies have also garnered attention as adjunctive approaches. Agents that mitigate endothelial activation and oxidative stress, including N-acetylcysteine and statins, may help restore vascular homeostasis and reduce the pro-thrombotic environment characteristic of SCA. Moreover, therapies aimed at correcting nitric oxide bioavailability are being explored to improve vasodilation and prevent ischemic injury [32]. Perhaps the most transformative innovations lie in gene-based therapies. Advances in gene editing technologies such as CRISPR-Cas9 and lentiviral vector-mediated gene addition offer potential curative solutions by either reactivating endogenous HbF or directly correcting the β-globin gene mutation. Early clinical trials demonstrate encouraging safety and efficacy profiles, heralding a new era in SCA treatment. However, challenges related to accessibility, cost, and long-term outcomes remain critical considerations [33].

Challenges

Despite remarkable progress in understanding the molecular mechanisms underlying VOCs and the development of innovative preventive therapies, numerous challenges impede the widespread implementation and efficacy of these advances in SCD management. These challenges span biological, clinical, socioeconomic, and healthcare delivery domains, complicating efforts to reduce VOC burden globally [34]. Biologically, the heterogeneity of SCD presents a significant obstacle. Variability in genetic modifiers, co-existing conditions, and individual

responses to therapy complicate the prediction of VOC risk and treatment outcomes. Some patients exhibit suboptimal or no response to established therapies such as hydroxyurea, necessitating personalized treatment approaches. Furthermore, the multifactorial pathophysiology of VOCs involves redundant and overlapping pathways, making it difficult to identify singular therapeutic targets that can comprehensively prevent crises [35]. Clinically, adherence to preventive therapies remains a major challenge. Hydroxyurea, although effective, requires long-term commitment and regular monitoring, which can be hindered by medication side effects, limited patient education, and mistrust of healthcare systems. Similarly, newer agents like crizanlizumab require intravenous administration and are often costly, limiting their accessibility and acceptability, particularly in low-resource settings where SCD is most prevalent [36].

Socioeconomic factors further exacerbate these challenges. Many individuals with SCD live in regions with limited healthcare infrastructure, inadequate screening programs, and poor access to specialist care. This leads to delayed diagnosis, insufficient preventive care, and increased risk of complications. Financial barriers, lack of insurance coverage, and transportation difficulties also reduce consistent access to medications and follow-up [37]. From a healthcare systems perspective, disparities in provider knowledge and resources hinder the optimal management of SCD. There is often insufficient training in the latest SCD therapies, resulting in underutilization of available treatments. Additionally, fragmented care coordination and lack of comprehensive multidisciplinary teams can impede holistic management necessary for VOC prevention [38]. Ethical and logistical challenges accompany the emerging gene therapy approaches. While gene editing offers the promise of a potential cure, concerns about long-term safety, off-target effects, and equitable access persist. The high cost and complexity of these therapies mean that many patients, especially in low- and middle-income countries, may not benefit from these advances for years to come [39].

Future Perspectives

As the understanding of SCD and VOCs deepens, future perspectives in prevention and management are increasingly focused on personalized medicine, technological innovation, and expanding global access to advanced therapies. The ongoing integration of molecular insights with clinical practice promises to revolutionize the approach to VOC prevention [40]. One promising avenue is the refinement of precision medicine strategies. Advances in genomics and biomarker discovery may enable risk stratification of patients based on individual molecular and clinical profiles, allowing tailored preventive regimens. For example, identifying genetic modifiers that influence disease severity or therapy responsiveness could optimize hydroxyurea dosing or inform selection of novel agents, thereby maximizing efficacy while minimizing adverse effects [41]. The continued development of gene editing technologies, such as CRISPR-Cas9, base

editing, and prime editing, holds transformative potential. These approaches aim not only to correct the underlying genetic mutation but also to induce sustained fetal hemoglobin production, providing durable protection against sickling. Ongoing clinical trials will clarify the long-term safety and efficacy of these therapies, and efforts to simplify delivery methods and reduce costs will be critical to broaden their availability worldwide [42].

Emerging pharmacological agents targeting new molecular pathways involved in VOC pathogenesis are also under exploration. These include inhibitors of inflammatory mediators, modulators of oxidative stress, and novel adhesion blockers. The combination of multiple targeted therapies may address the complex and redundant mechanisms of vaso-occlusion more effectively than monotherapy, heralding a new era of combination preventive treatment [43]. Digital health technologies, including mobile health applications and remote monitoring tools, are poised to improve adherence and early detection of VOCs. Patient-centered platforms that facilitate education, symptom tracking, and communication with healthcare providers can empower individuals with SCD to engage actively in their care, potentially reducing crisis frequency and severity [44]. Equally important is the expansion of healthcare infrastructure and policies to support comprehensive SCD care globally. Investment in newborn screening, early intervention programs, and multidisciplinary care models will enhance preventive efforts. International collaborations and partnerships can facilitate knowledge sharing, capacity building, and equitable distribution of novel therapies [44].

Conclusion

VOCs remain a formidable challenge in the management of sickle cell disease, significantly impacting patient morbidity and quality of life. Recent innovations have expanded our therapeutic arsenal from conventional treatments like hydroxyurea to targeted molecular agents, monoclonal antibodies, and gene-based therapies. These advances, grounded in a deeper understanding of the complex molecular pathophysiology of VOCs, offer promising avenues for more effective prevention and improved patient outcomes. However, significant challenges persist, including biological variability, treatment adherence, healthcare disparities, and access to novel therapies, especially in resource-limited settings where the burden of sickle cell disease is highest. Addressing these challenges will require integrated approaches combining personalized medicine, technological innovations, robust healthcare infrastructure, and policies promoting equitable care.

References

1. Verma HK, Lakkakula S, Lakkakula BV. Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease. Acta Haematologica Polonica. 2018;49(1):1-8.
2. Iughetti L, Bigi E, Venturelli D. Novel insights in the management of sickle cell disease in childhood. World journal of clinical pediatrics. 2016;5(1):25.

3. Detterich JA. Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy? Clinical hemorheology and microcirculation. 2018;68(2-3):173-86.
4. Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax. 2011;66(9):804-9.
5. Lucarelli G, Isgrò A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harbor perspectives in medicine. 2012;2(5).
6. Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. European journal of haematology. 2020;105(3):237-46.
7. Owusu-Poku AG, Gyamfi D, Togbe E, Opoku S, Ephraim RK, Asibey JG, Sackey B, Boadu WI, Annani-Akollor ME, Anto EO, Addai-Mensah O. Interplay between fetal haemoglobin, micronutrients and oxidative stress biomarkers in sickle cell anaemia children. Human Nutrition & Metabolism. 2022; 30:200173.
8. Cronin RM, Wuichet K, Ghafuri DL, Hodges B, Chopra M, He J, Niu X, Kassim AA, Wilkerson K, Rodeghier M, DeBaun MR. Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy. Blood Advances. 2023;7(15):3775-82.
9. Vainauskienė V, Vaitkienė R. Enablers of patient knowledge empowerment for self-management of chronic disease: an integrative review. International journal of environmental research and public health. 2021;18(5):2247.
10. Verma HK, Lakkakula S, Lakkakula BV. Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease. Acta Haematologica Polonica. 2018;49(1):1-8.
11. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. The Journal of pediatrics. 1996;129(4):559-65.
12. McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert opinion on drug safety. 2015;14(11):1749-58.
13. Tolu SS, Van Doren L. Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review. Transfusion and Apheresis Science. 2022:103533.
14. Dexter D, McGann PT. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023.
15. Merritt AL, Haiman C, Henderson SO. Myth: blood transfusion is effective for sickle cell anemia—associated priapism. Canadian Journal of Emergency Medicine. 2006;8(2):119-22.
16. Al-Saeed HH, Al-Salem AH. Principles of blood transfusion in sickle cell anemia. Saudi medical journal. 2002;23(12):1443-8.
17. Adewoyin AS. Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa). Anemia. 2015 Jan 18;2015.
18. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood, The Journal of

the American Society of Hematology. 2009;114(25):5117-25.
19. Al-Saqladi AW, Maddi DM, Al-Sadeeq AH. Blood transfusion frequency and indications in Yemeni children with sickle cell disease. Anemia. 2020.
20. Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox sanguinis. 2009;97(3):185-97.
21. Ajmani PS, Ajmani PS. Transfusion Reactions. Immunohematology and Blood banking: Principles and Practice. 2020:175-95.
22. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood, The Journal of the American Society of Hematology. 2019;133(17):1854-64.
23. Puri L, Nottage KA, Hankins JS, Anghelescu DL. State of the art management of acute vaso-occlusive pain in sickle cell disease. Pediatric Drugs. 2018; 20:29-42.
24. Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Frontiers in physiology. 2020; 11:435.
25. Henig I, Zuckerman T. Hematopoietic stem cell transplantation—50 years of evolution and future perspectives. Rambam Maimonides medical journal. 2014;5(4).
26. Lovett J. Compact Gene Regulatory Cassettes Support Hallmark Features of T-cell Receptor (TCR)-a Gene Locus Control Region (LCR) Activity. City University of New York; 2018.
27. Fielding C, García-García A, Korn C, Gadomski S, Fang Z, Reguera JL, Pérez-Simón JA, Göttgens B, Méndez-Ferrer S. Cholinergic signals preserve haematopoietic stem cell quiescence during regenerative haematopoiesis. Nature Communications. 2022;13(1):543.
28. Carden MA, Fasano RM, Meier ER. Not all red cells sickle the same: contributions of the reticulocyte to disease pathology in sickle cell anemia. Blood reviews. 2020; 40:100637.
29. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert review of hematology. 2010;3(3):285-99.
30. Shankarkumar U. The human leukocyte antigen (HLA) system. International Journal of Human Genetics. 2004;4(2):91-103.
31. Deeg HJ, Klingemann HG, Phillips GL. A guide to bone marrow transplantation. Springer Science & Business Media; 2012.
32. Wingard JR, Vogelsang GB, Deeg HJ. Stem cell transplantation: supportive care and long-term complications. ASH Education Program Book. 2002 ;2002(1):422-44.
33. Kapoor S, Little JA, Pecker LH. Advances in the treatment of sickle cell disease. InMayo Clinic Proceedings 2018;93(12):1810-1824.
34. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood, The Journal of the American Society of Hematology. 2011;118(5):1197-207.
35. Gotlib J, Becker PS, Coetzer T, Cuker A, Garcia D, George TI, Hoggatt J, Johnson P, Koury MJ, LaCasce A, Quinn CT. A Call to Action on Sickle Cell Disease. Nature.;518:107-10.
36. Mann-Jiles V, Morris DL. Quality of life of adult patients with sickle cell disease. Journal of the American Association of Nurse Practitioners. 2009;21(6):340-9.
37. Izgu N, Gok Metin Z, Karadas C, Ozdemir L, Metinarikan N, Corapcıoglu D. Progressive

muscle relaxation and mindfulness meditation on neuropathic pain, fatigue, and quality of life in patients with type 2 diabetes: a randomized clinical trial. Journal of Nursing Scholarship. 2020;52(5):476-87.

38. Phelan I, Furness PJ, Matsangidou M, Babiker NT, Fehily O, Thompson A, Carrion-Plaza A, Lindley SA. Designing effective virtual reality environments for pain management in burn-injured patients. Virtual Reality. 2023;27(1):201-15.
39. Johansson MB, Carlsson M, Sonnander K. Communication difficulties and the use of communication strategies: from the perspective of individuals with aphasia. International journal of language & communication disorders. 2012;47(2):144-55.
40. Lawrance E, Thompson R, Fontana G, Jennings N. The impact of climate change on mental health and emotional wellbeing: current evidence and implications for policy and practice. Avalable at: https://www. imperial. ac. uk/grantham/publications/all-publications/the-impact-of-climate-change-on-mentalhealth-and-emotional-wellbeing-current-evidence-and-implications-for-policy-and-practice. php. 2021.
41. Douglas P, Hescox M. Caring for creation: The evangelical's guide to climate change and a healthy environment. Baker Books; 2016.
42. Wahyuningsih S, Afiyanti Y, Waluyo A, Fitch MI. Non-Pharmacological Management of Nausea and Vomiting in Cancer: A Scoping Review. Jurnal Keperawatan Indonesia. 2023;26(1):20-35.
43. Abdo S, Nuseir KQ, Altarifi AA, Barqawi M, Ayoub NM, Mukkatash TL. Management of Sickle Cell Disease Pain among Adolescent and Pediatric Patients. Brain Sciences. 2019;9(8):182.
44. Kusnanto K, Sari NP, Harmayetty H, Efendi F, Gunawan J. Self-care model application to improve self-care agency, self-care activities, and quality of life in patients with systemic lupus erythematosus. Journal of Taibah University medical sciences. 2018;13(5):472-478.